Arctic Vision

  • Arctic Vision and Santen Ink Deal for ARVN001 Commercialization in China

    Arctic Vision and Santen Ink Deal for ARVN001 Commercialization in China

    China-based ophthalmology specialist, Arctic Vision, has entered into a strategic collaboration with Japan’s Santen Pharmaceutical (TYO: 4536) for the commercialization of ARVN001, an innovative triamcinolone acetonide suprachoroidal injectable suspension. This partnership marks a significant step in the expansion of ophthalmic treatments, with Santen securing exclusive commercialization rights in mainland China…

Fineline Info & Tech